Josh Riggs - Aug 15, 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
CEO and President, Director
Signature
/s/ Josh Riggs
Stock symbol
OCX
Transactions as of
Aug 15, 2023
Transactions value $
$0
Form type
4
Date filed
8/17/2023, 06:57 PM
Previous filing
Jun 13, 2023
Next filing
Apr 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +40K $0.00 40K Aug 15, 2023 Common Stock 40K $3.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.